Skip to main navigation menu Skip to main content Skip to site footer

No. 1 (2015)

NEW MEDICINES

Rispolept Consta — 10 years of practice in Russia: some conclusions

Published 2015-03-24

  • E.V. Oleneva
    • ,
  • S.G. Kapiletti
    • ,
  • P.V. Ryvkin
    • ,
  • M.J. Ladyzhenskii

E.V. Oleneva
Moscow Research Institute of Psychiatry - Branch of the V.P. Serbsky National Medical Research Center of Psychiatry and Narcology of the Ministry of Health of the Russian Federation

S.G. Kapiletti
Federal Medical Research Centre of Psychiatry and Narcology

P.V. Ryvkin
Federal Medical Research Centre of Psychiatry and Narcology

M.J. Ladyzhenskii
Federal Medical Research Centre of Psychiatry and Narcology

Abstract

The article presents a literature review of the new world research on risperidone longMacting injectable (RLAI) (Rispolept CONSTA) and summarizes a10-year experience of its use in Russia. RLAI was the first long-acting antipsychotic with the unique technology of biopolymeric microspheres, which combined advantages of longMterm action with the efficacy and safety of the second-generation antipsychotics. The guaranteed and controlled release drug delivery provide better adherence and achievement of more stable and deep remissions, which are associated with less exacerbations, drop in hospitalization rate, higher levels of functioning and quality of life and with better outcomes in general.

Keywords

schizophrenia, antipsychotics, longMterm maintenance treatment, risperidone long-acting injectable (RLAI), outpatients’ compliance, treatment adherence, remission

PDF (Русский)

Downloads

Download data is not yet available.